Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $10.00 to $24.00 in a research report issued on Friday,Benzinga reports ...